Home・Lista de Ações・Alkermes PLC

Alkermes PLC

Abrir

SetorSaúde

48.98 1.28

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

47.96

Máximo

49.4

Indicadores-chave
By Trading Economics
Rendimento	67M 501K
Vendas	103M 496M
P/E Médio do Setor	130.342 68.51
EPS	0.52
Margem de lucro	0.101
Funcionários	2,050
EBITDA	76M 54M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+20.43% upside

Dividendos
By Acuity
Próximos Ganhos	27 de out. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-480M 8.3B
Abertura anterior	47.7
Fecho anterior	48.98

Sentimento de Notícias

By Acuity

10%

90%

14 / 340 Ranking em Healthcare

Alkermes PLC Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de ago. de 2026, 19:36 UTC

Alkermes Plc shares are lower today, reflecting unusual volatility and trading significantly below the 20-day moving average. No specific news was identified.

5 de ago. de 2026, 19:56 UTC

Alkermes Plc shares are lower Wednesday, continuing a decline since Tuesday's close, despite broader market optimism from falling oil prices and potential diplomatic resolutions.

4 de ago. de 2026, 19:26 UTC

News

Alkermes Plc shares are lower today amid concerns over recent insider sales by executives, despite the company's gross margin of 80.22%.

3 de ago. de 2026, 20:02 UTC

Alkermes shares are higher today, driven by significant gains in the overall market and major technology stocks, despite earlier session pullbacks.

31 de jul. de 2026, 19:36 UTC

Alkermes Plc shares are lower today, impacted by declines in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

30 de jul. de 2026, 19:58 UTC

Alkermes Plc shares are higher during Thursday's session, reflecting a broader recovery in tech shares despite remaining below the 20-day moving average.

29 de jul. de 2026, 20:03 UTC

News

Macro Event

Shares declining despite price target increases from JP Morgan, Baird.

28 de jul. de 2026, 20:02 UTC

News

Event

Alkermes Plc shares are lower after reporting second-quarter earnings of 0 cents per share, below the consensus estimate of 29 cents.

24 de jul. de 2026, 19:46 UTC

Alkermes Plc shares are lower today, pulling back after an early high. No specific news has been identified to explain the decline.

22 de jul. de 2026, 19:36 UTC

Alkermes Plc shares are lower today, despite an earlier session high, amid rising crude oil prices and concerns over potential supply disruptions.

21 de jul. de 2026, 18:46 UTC

Alkermes shares are higher today, supported by improved market sentiment and renewed interest in AI stocks. The asset is trading near its one-month range high.

20 de jul. de 2026, 22:01 UTC

Alkermes Plc shares declined after-market, retracing from earlier peaks. The asset is currently below its 20-day moving average.

Comparação entre Pares

Variação de preço

Alkermes PLC Previsão

Preço-alvo

By TipRanks

20.43% parte superior

Previsão para 12 meses

Média 58.25 USD 20.43%

Máximo 65 USD

Mínimo 38 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para Alkermes PLC - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

12 ratings

Comprar

Manter

Vender

Com base em 12 analistas que deram avaliações de ações para Alkermes PLC - Dist nos últimos 3 meses.

Sentimento

By Acuity

14 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.